Rowan Chapman Sells 122 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 122 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $191.38, for a total value of $23,348.36. Following the sale, the director directly owned 5,752 shares of the company’s stock, valued at approximately $1,100,817.76. This trade represents a 2.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Natera Stock Down 0.3%

Shares of Natera stock opened at $197.79 on Thursday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The business’s fifty day simple moving average is $216.79 and its 200-day simple moving average is $207.08. The firm has a market cap of $28.03 billion, a PE ratio of -129.27 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same period in the prior year, the business posted ($0.41) EPS. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. Robert W. Baird lifted their price target on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. Barclays increased their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Wells Fargo & Company boosted their target price on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $253.47.

Institutional Trading of Natera

A number of large investors have recently made changes to their positions in NTRA. Mozayyx Management LLC purchased a new position in Natera in the fourth quarter worth approximately $309,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Natera in the 4th quarter valued at approximately $175,000. Reflection Asset Management purchased a new stake in shares of Natera in the 4th quarter valued at approximately $29,000. Tobam raised its holdings in shares of Natera by 24,935.0% in the 4th quarter. Tobam now owns 5,007 shares of the medical research company’s stock valued at $1,147,000 after purchasing an additional 4,987 shares in the last quarter. Finally, Groupama Asset Managment raised its holdings in shares of Natera by 19.5% in the 4th quarter. Groupama Asset Managment now owns 92,256 shares of the medical research company’s stock valued at $21,135,000 after purchasing an additional 15,072 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.